Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol...

Por Sarah R. Brown, Andrew Hall, Hannah L. Buckley, Louise Flanagan, David Gonzalez de Castro, Kate Farnell, Laura Moss, Rebecca Gregory, Kate Newbold, Yong Du, Glenn Flux, Jonathan Wadsley
Publicado em 2019-06-01